share_log

RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target

Benzinga ·  Nov 7 00:18  · Ratings

RBC Capital analyst Luca Issi reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Sector Perform and maintains $53 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment